• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Akero Therapeutics Inc (NQ: AKRO )

    26.76 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1
    Open 26.76
    Bid (Size) 25.08 (1)
    Ask (Size) 27.50 (1)
    Prev. Close 26.76
    Today's Range 26.76 - 26.76
    52wk Range 11.25 - 53.77
    Shares Outstanding 50,086,978
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
    Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of... 
    Via Benzinga
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire

    Performance

    YTD
    +13.97%
    +13.97%
    1 Month
    +15.34%
    +15.34%
    3 Month
    +28.72%
    +28.72%
    6 Month
    +19.73%
    +19.73%
    1 Year
    -37.97%
    -37.97%

    More News

    Read More
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    AKERO THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
    From The Rosen Law Firm PA
    Via GlobeNewswire
    SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
    From Schall Law
    Via GlobeNewswire
    Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
    From Akero Therapeutics Inc.
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.